Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Pinus Echinata Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of Shortleaf Pine pollen allergies. It belongs to the class of pollen allergenic extracts used in skin testing and subcutaneous immunotherapy.
Name
Pinus Echinata Pollen
Raw Name
PINUS ECHINATA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
4
Variant Count
4
Last Verified
February 17, 2026
About Pinus Echinata Pollen
Pinus Echinata Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of Shortleaf Pine pollen allergies. It belongs to the class of pollen allergenic extracts used in skin testing and subcutaneous immunotherapy.
Detailed information about Pinus Echinata Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Pinus Echinata Pollen.
Pinus Echinata Pollen, derived from the Shortleaf Pine tree, is a biological substance utilized primarily in the field of clinical allergy and immunology. It belongs to a class of drugs known as Non-Standardized Pollen Allergenic Extracts [EPC]. These extracts are complex mixtures of proteins, glycoproteins, and polysaccharides harvested from the male cones of the Pinus echinata species, which is native to the Eastern and Southeastern United States. In clinical practice, these extracts serve two primary functions: as a diagnostic tool to identify patients with Type I hypersensitivity (allergic) reactions to pine pollen, and as a therapeutic agent in allergen immunotherapy (AIT), commonly referred to as allergy shots.
As a member of the non-standardized extract class, Pinus Echinata Pollen is characterized by the fact that its potency is not measured by a federally established reference standard (such as Bioequivalent Allergy Units or BAU). Instead, it is typically prepared and labeled based on weight/volume (w/v) ratios or protein nitrogen units (PNU). This distinction is critical for healthcare providers to understand, as it necessitates careful titration when switching between different manufacturers or lots. The FDA has historically regulated these biological products under the Public Health Service Act, ensuring that while they are 'non-standardized,' they meet rigorous purity and identity requirements.
The mechanism of action for Pinus Echinata Pollen depends entirely on its clinical application. In diagnostic settings, such as skin prick testing (SPT) or intradermal testing, the extract works by introducing specific pine pollen allergens directly into the skin's dermal or epidermal layers. If a patient is sensitized, these allergens cross-link specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells and basophils. This cross-linking triggers a rapid degranulation process, releasing inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This results in a localized 'wheal and flare' reaction (a raised bump surrounded by redness), which clinicians measure to determine the degree of sensitivity.
In therapeutic applications (immunotherapy), the mechanism is more complex and involves a fundamental shift in the patient's immune response. By administering gradually increasing doses of the Pinus Echinata Pollen extract over several months, the body moves from a Th2-dominated allergic response to a Th1-dominated or regulatory T-cell (Treg) response. This process induces the production of 'blocking antibodies,' specifically Immunoglobulin G4 (IgG4), which compete with IgE for allergen binding. Over time, this reduces mast cell reactivity and decreases the recruitment of eosinophils to the respiratory mucosa, leading to a long-term reduction in allergy symptoms such as rhinitis, conjunctivitis, and allergic asthma.
Unlike small-molecule drugs, the pharmacokinetics of Pinus Echinata Pollen (a biological extract) do not follow traditional ADME (Absorption, Distribution, Metabolism, and Excretion) models.
Pinus Echinata Pollen is FDA-indicated for the following uses:
Pinus Echinata Pollen is primarily available in the following forms:
> Important: Only your healthcare provider can determine if Pinus Echinata Pollen is right for your specific condition.
Dosage for Pinus Echinata Pollen is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels.
Immunotherapy is divided into two phases:
Pinus Echinata Pollen extracts are generally considered safe for pediatric use in children over the age of 5. Dosing protocols are similar to adult protocols but require extreme caution due to the higher risk of systemic reactions in younger children. For children under 5, the risk-benefit ratio must be carefully weighed by a specialist, as the child may have difficulty communicating the early signs of a systemic reaction.
No dosage adjustment is typically required for patients with renal impairment, as the proteins are not cleared via the kidneys in a manner that affects toxicity.
No dosage adjustment is required for hepatic impairment, as the extract does not undergo hepatic metabolism.
Elderly patients may have a higher risk of cardiovascular complications if a systemic reaction occurs. Dosage should be approached conservatively, and the patient's ability to tolerate epinephrine (the primary treatment for anaphylaxis) must be assessed.
Pinus Echinata Pollen extracts must only be administered by a healthcare professional in a clinical setting equipped to treat anaphylaxis.
If a dose of immunotherapy is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to maintain safety. If a dose is missed during the maintenance phase by more than 1-2 weeks, the physician may reduce the dose and then gradually increase it again. Never 'double up' on doses to make up for a missed one.
An overdose of Pinus Echinata Pollen occurs if a dose higher than the patient's current tolerance level is administered. Signs of overdose include severe local swelling (greater than 10 cm), generalized hives, wheezing, throat tightness, or a drop in blood pressure. Immediate treatment involves the administration of epinephrine (1:1000) and emergency medical support.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
The most frequent side effects associated with Pinus Echinata Pollen are localized to the site of administration. These are expected responses to the introduction of an allergen into a sensitized individual.
These reactions are often referred to as 'large local reactions' or mild systemic symptoms.
These side effects are less frequent but indicate a higher level of systemic sensitivity.
> Warning: Stop taking Pinus Echinata Pollen and call your doctor immediately if you experience any of these.
There is no evidence that Pinus Echinata Pollen causes long-term organ damage or cumulative toxicity. The primary 'long-term' effect is the desired desensitization of the immune system. However, patients who receive immunotherapy for many years may develop small areas of subcutaneous thickening (nodules) at the frequent injection sites. These are generally benign but should be monitored by a physician.
Allergenic extracts, including Pinus Echinata Pollen, can cause severe, life-threatening systemic reactions, including anaphylaxis. Because of this risk, the following safety measures are mandatory:
Report any unusual symptoms to your healthcare provider.
Pinus Echinata Pollen is a potent biological agent. It is intended for use only by physicians specializing in allergy and immunology. Patients must be informed that the goal of treatment is to induce a controlled allergic response, which inherently carries the risk of an uncontrolled systemic reaction. It is vital that patients are honest about their current health status, especially respiratory health, before every single injection.
No FDA black box warnings are currently issued for Pinus Echinata Pollen specifically, but it falls under the general class warning for all allergenic extracts regarding the risk of severe systemic reactions and anaphylaxis. The warning emphasizes that these products are not interchangeable with extracts from other manufacturers without careful clinical consideration.
Pinus Echinata Pollen does not typically cause sedation. However, if a patient experiences a systemic reaction or receives antihistamines/epinephrine to treat a reaction, their ability to drive or operate machinery may be significantly impaired. It is generally recommended to wait at least 30 minutes after an injection before driving.
There is no direct interaction between alcohol and Pinus Echinata Pollen. However, alcohol consumption can cause vasodilation, which may theoretically increase the rate of allergen absorption or worsen the symptoms of an allergic reaction. It is best to avoid alcohol for several hours after an injection.
Immunotherapy is usually discontinued after 3 to 5 years of successful maintenance. There is no withdrawal syndrome associated with stopping Pinus Echinata Pollen. However, if treatment is stopped prematurely, the patient's allergy symptoms are likely to return to their baseline levels over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Pinus Echinata Pollen.
There are no known direct food-drug interactions with Pinus Echinata Pollen. However, patients with 'Pollen-Food Allergy Syndrome' (Oral Allergy Syndrome) may find that their sensitivity to certain raw fruits or vegetables increases during their immunotherapy build-up phase. This is due to cross-reactivity between pollen proteins and food proteins.
For each major interaction, the mechanism usually involves either the interference with the immune cascade (antihistamines) or the interference with emergency rescue medications (beta-blockers). The clinical consequence is either a loss of diagnostic utility or an increased risk of mortality during a reaction.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Pinus Echinata Pollen must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients allergic to Pinus Echinata may also show cross-sensitivity to other pine species (e.g., Pinus taeda or Pinus strobus) and occasionally to other conifers. This is due to the similarity in the protein structures of the pollen grains. If a patient is known to be highly sensitive to one type of pine, the initial dose of Pinus Echinata Pollen should be extremely low.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Pinus Echinata Pollen.
Pinus Echinata Pollen is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not direct toxicity to the fetus, but the danger of maternal anaphylaxis. If the mother experiences a severe systemic reaction, her blood pressure may drop, leading to decreased placental perfusion and fetal distress. Most allergists recommend continuing maintenance doses if the patient is already stable but advise against starting the build-up phase during pregnancy.
It is not known whether the allergenic proteins from Pinus Echinata Pollen are excreted in human milk. However, since these are large proteins that are degraded into amino acids, it is highly unlikely they would reach the infant in any significant amount. Breastfeeding is generally considered safe for women receiving immunotherapy, provided they do not have a systemic reaction.
Immunotherapy with Pinus Echinata Pollen is generally indicated for children 5 years of age and older. The safety and efficacy in children under 5 have not been established. Younger children may be unable to articulate the early symptoms of a systemic reaction (such as an itchy throat or a 'funny' feeling), which can delay the administration of life-saving treatment.
Clinical studies of allergenic extracts did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The risk of cardiac events during anaphylaxis is the primary concern for this population.
There are no specific guidelines for the use of Pinus Echinata Pollen in patients with renal impairment. Because the product is a biological protein and is not primarily cleared by the kidneys, standard dosing is usually appropriate. However, if the patient is on dialysis or has unstable fluid status, the risk of hypotension during a reaction may be increased.
No dosage adjustments are required for patients with liver disease. The metabolic pathway of allergenic proteins does not involve the liver's enzymatic systems.
> Important: Special populations require individualized medical assessment.
At the molecular level, Pinus Echinata Pollen contains specific proteins (allergens) that are recognized by the immune system. In a sensitized individual, B-cells have produced IgE antibodies that are 'primed' to these pine proteins. These IgE antibodies are bound to FceRI receptors on mast cells. When the Pinus Echinata extract is injected, the allergens cross-link these IgE antibodies, causing an influx of calcium into the mast cell and the subsequent release of histamine and other inflammatory mediators. During immunotherapy, the repeated exposure to these allergens induces T-regulatory cells to produce IL-10 and TGF-beta, which suppress the Th2 allergic response and promote the production of IgG4 'blocking' antibodies.
The pharmacodynamic effect of a diagnostic dose is visible within 15-20 minutes as a wheal and flare reaction. The therapeutic effect of immunotherapy is much slower, usually requiring 6-12 months of consistent treatment before a significant reduction in clinical symptoms is observed. The duration of effect can last for several years after the 3-5 year treatment course is completed.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Local/Subcutaneous) |
| Protein Binding | N/A (Biological Protein) |
| Half-life | Hours (for protein fragments) |
| Tmax | 15-30 minutes (local reaction) |
| Metabolism | Proteolytic degradation |
| Excretion | Cellular turnover/Minimal Renal |
Pinus Echinata Pollen extract is not a single chemical entity with a molecular formula. It is a biological mixture. The active components are proteins ranging from 10 kDa to over 70 kDa in molecular weight. The extract is typically prepared in a 0.9% saline solution with 0.4% phenol as a preservative and may contain 50% glycerin for stability.
It is classified as a Non-Standardized Pollen Allergenic Extract. Related medications include other pine extracts (Pinus Taeda), grass pollen extracts (Timothy, Orchard), and weed pollen extracts (Ragweed).
Common questions about Pinus Echinata Pollen
Pinus Echinata Pollen extract is primarily used for the diagnosis and treatment of allergies to Shortleaf Pine pollen. In diagnostic settings, it is applied during skin prick or intradermal testing to confirm if a patient has an IgE-mediated sensitivity to this specific tree. For treatment, it is used in allergen immunotherapy (allergy shots) to help desensitize the immune system over time. This can significantly reduce symptoms like sneezing, itchy eyes, and congestion in patients who live in areas where Shortleaf Pine is prevalent. It is only used after a formal diagnosis by an allergy specialist.
The most common side effects are localized reactions at the site of the injection or skin test. These include redness, swelling, and itching, which typically appear within minutes and resolve within a few hours. Some patients may experience 'large local reactions' where the swelling exceeds several inches in diameter. While these are common, they are generally not dangerous but should be reported to your doctor. Rarely, patients may feel mild fatigue or a temporary increase in their usual allergy symptoms shortly after the procedure.
While there is no direct chemical interaction between alcohol and Pinus Echinata Pollen, it is generally advised to avoid alcohol for several hours after receiving an allergy injection. Alcohol causes blood vessels to dilate, which could theoretically speed up the absorption of the allergen into your bloodstream and increase the risk of a systemic reaction. Furthermore, alcohol can mask the early symptoms of an allergic reaction, such as feeling flushed or lightheaded. To ensure maximum safety during the 30-minute observation period and the hours following, it is best to remain sober. Always consult your allergist for their specific clinic policies regarding alcohol.
The safety of starting Pinus Echinata Pollen immunotherapy during pregnancy has not been established, and it is generally avoided. The main risk is not the extract itself, but the potential for a severe allergic reaction (anaphylaxis) in the mother, which could deprive the fetus of oxygen. However, if a woman is already on a stable maintenance dose of immunotherapy and becomes pregnant, many doctors will continue the treatment as the risk of a reaction is much lower. Decisions regarding immunotherapy during pregnancy are made on a case-by-case basis by weighing the severity of the mother's allergies against the risks of treatment. You should inform your allergist immediately if you become pregnant.
For diagnostic purposes, the extract works almost immediately, with results appearing within 15 to 20 minutes of a skin test. However, for therapeutic immunotherapy, the process is much slower and requires patience. Most patients begin to feel a reduction in their allergy symptoms toward the end of the 'build-up phase,' which usually takes 3 to 6 months. Significant and long-lasting relief typically occurs after 12 months of consistent maintenance injections. To achieve the full benefit and long-term desensitization, the treatment is usually continued for a total of 3 to 5 years.
Yes, you can stop taking Pinus Echinata Pollen injections suddenly without experiencing a 'withdrawal' in the traditional sense. Unlike some medications, your body does not become physically dependent on allergenic extracts. However, stopping the treatment before the recommended 3-to-5-year course is finished will likely result in the return of your allergy symptoms. The immune system may gradually lose the desensitization it has gained, and you may find yourself needing antihistamines and other medications again. It is always best to discuss your treatment goals with your allergist before deciding to discontinue therapy.
If you miss a scheduled immunotherapy injection, you should contact your allergy clinic as soon as possible to reschedule. Do not attempt to 'make up' the dose at home or take a higher dose next time. Depending on how long it has been since your last injection, your doctor may need to repeat your last dose or even reduce the dose slightly to ensure your safety. This is because your tolerance to the allergen can decrease if too much time passes between doses. Consistency is key to the success of the treatment, so try to stick to your schedule as closely as possible.
There is no clinical evidence to suggest that Pinus Echinata Pollen or allergen immunotherapy causes weight gain. The extract consists of natural proteins and a small amount of stabilizer (like glycerin or phenol), which do not have metabolic effects on fat storage or appetite. If you experience weight changes while on immunotherapy, they are likely due to other factors, such as lifestyle changes or other medications you may be taking (like oral steroids for asthma). If you have concerns about weight gain, you should discuss them with your primary care physician.
Pinus Echinata Pollen can be taken alongside most common medications, but there are some critical exceptions. You must inform your doctor if you are taking beta-blockers, as these can make it very difficult to treat a severe allergic reaction if one occurs. Additionally, you should stop taking antihistamines several days before a diagnostic skin test, as they will block the reaction and lead to inaccurate results. Most other medications, such as those for blood pressure (except ACE inhibitors and beta-blockers), cholesterol, or diabetes, do not interfere with the treatment. Always provide a full list of your current medications to your allergist.
Allergenic extracts like Pinus Echinata Pollen are biological products rather than simple chemical drugs, so the term 'generic' does not apply in the same way it does to tablets like ibuprofen. However, several different biological manufacturers produce Pinus Echinata extracts. While these products are similar, they are 'non-standardized,' meaning the potency can vary between different brands. Because of this, your doctor will generally try to keep you on the same manufacturer's product throughout your treatment. If a switch is necessary, your doctor will likely reduce your dose temporarily to ensure you tolerate the new extract safely.